

# Arianna Zangrilli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9566972/publications.pdf>

Version: 2024-02-01

25  
papers

387  
citations

1039406

9  
h-index

794141

19  
g-index

25  
all docs

25  
docs citations

25  
times ranked

564  
citing authors

#	ARTICLE	IF	CITATIONS
1	Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk. <i>International Journal of Dermatology</i> , 2022, 61, 577-581.	0.5	4
2	Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography. <i>Dermatology Practical and Conceptual</i> , 2022, 12, e2022011.	0.5	1
3	Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. <i>Dermatologic Therapy</i> , 2022, 35, e15489.	0.8	13
4	Improvement of Psoriasis Using Oral Probiotic <i>Streptococcus salivarius</i> K-12: a Case-Control 24-Month Longitudinal Study. <i>Probiotics and Antimicrobial Proteins</i> , 2022, 14, 573.	1.9	4
5	Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1291-1298.	1.4	5
6	A linear forehead lesion caused by intralesional injection of triamcinolone acetonide and treated with hyaluronic acid filler: Case report. <i>Dermatologic Therapy</i> , 2020, 33, e14526.	0.8	3
7	Risankizumab: How to choose the right dose in clinical practice?. <i>Dermatologic Therapy</i> , 2020, 33, e14371.	0.8	0
8	Omalizumab and adalimumab: a winning couple. <i>Immunotherapy</i> , 2020, 12, 1287-1292.	1.0	4
9	Paradoxical Psoriasis Induced by Anti-TNF $\alpha$ Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7873.	1.8	21
10	Ixekizumab: One drug for an enigmatic psoriasis. <i>Dermatologic Therapy</i> , 2020, 33, e13869.	0.8	1
11	Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. <i>Journal of Dermatology</i> , 2020, 47, 578-582.	0.6	34
12	Efficacy and safety of adalimumab in difficult-to-treat psoriasis. <i>Dermatologic Therapy</i> , 2020, 33, e13374.	0.8	14
13	One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast. <i>Dermatologic Therapy</i> , 2019, 32, e13089.	0.8	7
14	Adalimumab in severe plaque psoriasis of childhood: A multicenter, retrospective real-life study up to 52-weeks observation. <i>Dermatologic Therapy</i> , 2019, 32, e13091.	0.8	21
15	Efficacy and safety of adalimumab after failure of other anti-TNF $\alpha$ agents for plaque-type psoriasis: clinician behavior in real life clinical practice. <i>Journal of Dermatological Treatment</i> , 2019, 30, 441-445.	1.1	5
16	Is weekly dose of adalimumab a simple approach for resistant psoriasis?. <i>Journal of Dermatological Treatment</i> , 2018, 29, 233-234.	1.1	1
17	Paradoxical case effects of psoriasis following adalimumab therapy: A case series. <i>Dermatologic Therapy</i> , 2018, 31, e12729.	0.8	7
18	Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 146-154.	0.1	2

#	ARTICLE	IF	CITATIONS
19	HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 295-301.	1.6	13
20	PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, e42-e44.	0.6	57
21	Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. <i>European Journal of Dermatology</i> , 2015, 25, 64-69.	0.3	8
22	Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus. <i>Pediatrics International</i> , 2010, 52, e161-3.	0.2	2
23	Long-term efficacy of adalimumab in generalized pustular psoriasis. <i>Journal of Dermatological Treatment</i> , 2008, 19, 185-187.	1.1	29
24	Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 269-275.	0.6	121
25	Erysipeloid cutaneous metastasis from bladder carcinoma. <i>European Journal of Dermatology</i> , 2007, 17, 534-6.	0.3	10